Results 251 to 260 of about 58,906 (283)
Some of the next articles are maybe not open access.
Seminars in Reproductive Medicine, 1999
Cessation of ovarian estrogen secretion is the key event during the climacteric. An enzyme termed aromatase in a number of human tissues and cells, including ovarian granulosa cells, the placental syncytiotrophoblast, adipose and skin fibroblasts, bone, and the brain, catalyzes the conversion of C19 steroids to estrogens.
S E, Bulun +3 more
openaire +2 more sources
Cessation of ovarian estrogen secretion is the key event during the climacteric. An enzyme termed aromatase in a number of human tissues and cells, including ovarian granulosa cells, the placental syncytiotrophoblast, adipose and skin fibroblasts, bone, and the brain, catalyzes the conversion of C19 steroids to estrogens.
S E, Bulun +3 more
openaire +2 more sources
Aromatase and Leiomyoma of the Uterus
Seminars in Reproductive Medicine, 2004In leiomyoma of the uterus, both aromatase and 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type I are overexpressed compared with myometrium. This suggests that leiomyoma cells convert circulating androstenedione into estrone (via aromatase), then into the active form of estrogen, estradiol (via 17beta-HSD type I). In vitro experiments and several
Makio, Shozu +2 more
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 2003
Aromatase gene expression and activity have been studied in human skeletal muscle. Using two separate rounds of RT-nested PCR, transcripts from the coding region of aromatase mRNA were detected in 32 of 34 samples. In terms of the non-coding exon I, PCR product for I.4 was detected in 13 cases (38%), I.3 in 10 cases (29%), P.II in 6 cases (18%) and I.1
A A, Larionov +5 more
openaire +2 more sources
Aromatase gene expression and activity have been studied in human skeletal muscle. Using two separate rounds of RT-nested PCR, transcripts from the coding region of aromatase mRNA were detected in 32 of 34 samples. In terms of the non-coding exon I, PCR product for I.4 was detected in 13 cases (38%), I.3 in 10 cases (29%), P.II in 6 cases (18%) and I.1
A A, Larionov +5 more
openaire +2 more sources
American Journal of Clinical Oncology, 1995
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
Aromatase inhibitors and teratogenesis
Fertility and Sterility, 2004letter to the ...
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 2007
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer
Circulation, 2020Farzin Khosrow-Khavar +2 more
exaly